Disease · HP_0000741
Trials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 14 of 14
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02346201 | Apathy in Dementia Methylphenidate Trial 2 | Phase 3 | 200 | 2023-06-13 | Apathy, Alzheimer's Disease | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT00548652 | Role of Apathy in the Effectiveness of Weight Loss Interventions | Not applicable | 101 | 2019-10-04 | Obesity, Apathy | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT01117181 | Apathy in Dementia Methylphenidate Trial (ADMET) | Phase 2 | 60 | 2013-05-10 | Apathy, Alzheimer's Disease | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT04958031 | A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | Phase 2 | 41 | 2026-03-11 | Apathy in Dementia | RAZPIPADON | Its record names the disease | ClinicalTrials.gov |
| NCT01172145 | Treatment of Apathy in Alzheimer's Disease With Modafinil | Phase 3 | 22 | 2011-03-04 | Apathy, Alzheimer's Disease | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT02786667 | Non Motors Aspects in De Novo Parkinson's Disease | Phase 3 | 199 | Parkinson Disease, Apathy | ROTIGOTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03260920 | Intranasal Oxytocin for Frontotemporal Dementia | Phase 2 | 112 | Frontotemporal Dementia | OXYTOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01047254 | Bupropion for the Treatment of Apathy in Alzheimer's Dementia | Phase 3 | 110 | Apathy in Dementia | BUPROPION | Its record names the disease | ClinicalTrials.gov | |
| NCT06482554 | Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | Phase 3 | 80 | Apathy, Schizophrenia, Schizophrenia; Psychosis | LUMATEPERONE, RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00767091 | Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia | Phase 3 | 40 | Parkinson's Disease, Apathy, no Dementia | RIVASTIGMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01914965 | Apathy Cure Through Bupropion in Huntington's Disease | Phase 2 | 40 | Apathy, Huntington's Disease | BUPROPION | Its record names the disease | ClinicalTrials.gov | |
| NCT07279740 | Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia | Phase 2 | 12 | Alzheimer s Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease, Apathy, Apathy in Dementia | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05561205 | rTMS for Apathy Clinical Trial | Not applicable | 10 | Alzheimer Disease, Apathy in Dementia, Dementia, Mild Behavioural Impairment, Mild Cognitive Impairment, Neurocognitive Disorders | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05182151 | Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease. | 8 | Apathy, Parkinson Disease | ISTRADEFYLLINE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000741/trials